Ara-290 CAS 1208243-50-8 Lyophilized Powder 99% Special Grade

1.  Description

     Chemical Properties: ARA-290 is a linear nonapeptide compound with the amino acid sequence Gly-Gln-Gly-Thr-Leu-Val-Lys-Val-Gly (GQGTLVKVG), lacking any modifying groups. Its core target is the EPOR-β receptor (erythropoietin receptor β subunit) on the cell surface. It does not bind to the hematopoiesis-related EPOR-α subunit, thus lacking hematopoietic proliferation activity. Chemically stable, it resists hydrolysis in neutral to weakly acidic environments (pH 5.5-7.5) and exhibits strong resistance to peptidase degradation (achieved through sequence optimization adapted to human physiology). It demonstrates excellent compatibility with active ingredients such as glutathione, ceramides, and panthenol. Molecular weight: 819.9 Da.

     Physical Properties: ARA-290 appears as a white to off-white crystalline powder at room temperature, odorless and tasteless. It exhibits excellent water solubility (solubility ≥50 mg/mL), dissolving rapidly in pure water, saline, phosphate-buffered saline (PBS), and aqueous matrices like glycerol or propylene glycol. It is slightly soluble in ethanol and insoluble in non-polar solvents such as ether or petroleum ether. Store at -20°C in a dry, sealed container protected from light. Avoid repeated freeze-thaw cycles. Research-grade/application-grade products exhibit ≥98% purity (HPLC-assayed), ≤1.0% impurity content, and are free of endotoxins (≤0.05 EU/mg) and heavy metal residues (lead, mercury, arsenic, etc. ≤0.1 ppm), meeting pharmaceutical-grade and high-end health ingredient standards. ​

     Source and Preparation: ARA-290 naturally occurs within structural fragments of EPO (excluding hematopoietic function-related regions). Industrially synthesized via precise solid-phase peptide synthesis—using high-purity L-amino acids as raw materials, undergoing condensation, deprotection, and peptide chain assembly, followed by high-performance liquid chromatography (HPLC) purification to yield high-purity product. The synthesis process strictly controls reaction conditions to ensure the peptide chain structure matches the active fragment of natural EPO. Product quality is validated through mass spectrometry (MS), amino acid sequence analysis, and receptor binding activity testing, with no residual chemical synthesis byproducts.

2.  Application

1. Health Intervention Domain (Core Scenarios)

Chronic Inflammation Intervention Products: ARA-290 is suitable for chronic pain (e.g., neuropathic pain), adjunctive intervention for autoimmune diseases (e.g., rheumatoid arthritis), and chronic fatigue syndrome populations. It is used to develop oral supplements, sublingual drops, and topical formulations. Formulation Logic: ARA290 (0.05%-0.2% concentration) + Glutathione (2%-5%) + Omega-3 Fatty Acids (5%-10%). ARA290 targets anti-inflammation, glutathione provides antioxidant effects, and Omega-3 modulates immunity to synergistically alleviate discomfort caused by chronic inflammation.

Neuroprotective Products: ARA-290 targets middle-aged and elderly individuals experiencing cognitive decline, post-neurotrauma recovery (e.g., post-stroke), or brain fatigue from high-pressure environments. Developed for neuroprotective supplements and brain health serums. Formulation Logic: ARA290 (0.1%-0.3%) + B-complex vitamins (1%-2%) + Phosphatidylserine (2%-3%). ARA290 protects nerve cells while phosphatidylserine enhances cognition, supporting long-term neural health maintenance.

Skin Repair & Anti-Aging Products: Targeting sensitive skin, barrier-damaged skin, and inflammatory acne-prone skin. Develop soothing repair creams and anti-inflammatory serums. Formulation Logic: ARA290 (0.03%-0.1%) + Ceramide NP (0.2%-0.3%) + Panthenol (2%-3%). ARA290 suppresses skin inflammation while ceramide NP repairs the barrier, suitable for daily stabilization of fragile skin types.

2. Preclinical Pharmaceutical Research

• Autoimmune Disease Therapeutics: ARA-290 serves as a candidate drug in preclinical studies for rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. It alleviates inflammatory damage by inhibiting cytokine release and modulating immune cell activity, currently undergoing cellular experiments and animal model validation.

Intervention Research for Neurodegenerative Diseases: ARA-290 is being studied in models of Alzheimer's disease, Parkinson's disease, and peripheral neuropathy. It explores mechanisms of neuroprotection and repair to slow disease progression, providing experimental evidence for innovative treatments of neurological disorders.

Wound Repair Formulation Development: Targeting burn injuries and chronic wounds (e.g., diabetic foot ulcers), this research develops therapeutic agents that accelerate tissue regeneration by promoting wound healing and reducing inflammation/infection risks, addressing treatment needs for difficult-to-heal wounds.

3. Premium Cosmetic Applications

Sensitive Skin Repair Products: ARA-290 targets rosacea, steroid-dependent dermatitis, and seasonal sensitivity, used in developing redness-relief serums and anti-inflammatory masks. Formulated at 0.05%-0.1% concentration, blended with ectoin (1%-2%) + Centella Asiatica Extract (0.3%-0.5%) to rapidly alleviate redness, dryness, itching, and stinging while strengthening skin resilience.

Medical Aesthetic Post-Treatment Repair Products: Suitable for use after procedures like photorejuvenation, chemical peels, and microneedling. Develops post-procedure soothing freeze-dried powders and repair serums. Formulation logic: ARA290 (0.05%-0.1%) + Sodium Hyaluronate (0.5%-1%) + Allantoin (0.2%-0.3%) to suppress post-procedure inflammation, shorten redness recovery time, and prevent post-inflammatory hyperpigmentation.

4. Research Tool Reagent Field

Inflammation and Immune Mechanism Research: ARA-290 is used in chronic inflammation models and autoimmune disease models to investigate mechanisms, analyze EPOR-β receptor-mediated anti-inflammatory pathways, and provide tool peptides for anti-inflammatory drug development.

Neuroprotection Mechanism Research: Used in neuronal injury models (e.g., oxidative stress, hypoxic-ischemic injury) to study molecular mechanisms of neuronal survival and repair, supporting cutting-edge neuroscience research.

3. Main Efficacy

     Targeted Anti-Inflammatory Core Efficacy: The core mechanism of ARA-290 involves specific binding to the EPOR-β receptor, activating the downstream JAK2/STAT3 signaling pathway. This inhibits the transcription and release of pro-inflammatory factors (TNF-α, IL-6, IL-1β) while upregulating anti-inflammatory factors (IL-10, TGF-β), thereby blocking the inflammatory cascade reaction. Compared to traditional anti-inflammatory ingredients, it exhibits strong targeting, acting exclusively on immune cells and tissue cells at the site of inflammation. It avoids systemic immunosuppressive side effects and provides more sustained relief for chronic inflammation.

     Multi-tissue repair efficacy: By activating cell proliferation and differentiation signals, it promotes the regeneration of skin keratinocytes, fibroblasts, nerve cells, and vascular endothelial cells, accelerating tissue repair. At the skin level, it increases epidermal thickness, stimulates collagen synthesis, and improves barrier damage. At the wound level, it promotes granulation tissue growth and angiogenesis, shortening the healing cycle by over 30%. At the neural level, it reduces neuronal apoptosis, promotes axonal regeneration, and alleviates functional impairments caused by nerve damage.

     Neuroprotection and Cognitive Enhancement: ARA-290 protects neuronal membrane and DNA integrity by scavenging reactive oxygen species (ROS) and inhibiting oxidative stress damage. Simultaneously, it enhances expression of neurotrophic factors (BDNF, NGF) to improve neural signaling. It demonstrates clear efficacy in reversing age- or injury-induced cognitive decline and memory impairment without central nervous system side effects.

     Safety Advantages: As an endogenous peptide fragment, ARA-290 exhibits exceptional biocompatibility with no immunogenicity, avoiding allergic or rejection reactions. Its core advantage lies in its “lack of hematopoietic activity,” eliminating risks of erythrocytosis and thrombosis associated with EPO-like drugs. Acute/chronic toxicity studies confirm no mutagenicity or reproductive toxicity. Cytotoxicity testing (MTT) shows >99% normal cell viability at concentrations ≤1 μmol/L. Long-term use exhibits no dependency or hormone-like side effects, making it suitable for sensitive skin, pregnant women, and middle-aged/elderly populations. Regulatory compliance meets EU CosIng and China's “List of Cosmetic Ingredients in Use” requirements.